ARIES (BAY86-5321/17508) A phase IV/IIIb study managing neovascular age-related macular degeneration (nAMD) over 2 years with a treat and extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept – a randomized, open-label, active-controlled, parallel-group phase IV/IIIb study.
CENTERA (BAY86--5321/17514) A multi-center, single-arm, interventional phase 4 study to evaluate a treat and extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion.
FOCUS Study An open label first in human phase 1/2 multicentre study to evaluate the safety, dose response and efficacy of GT005 administered as a single subretinal injection in subjects with macular atrophy due to age-related macular degeneration.
KITE (CRTH258B2302) A two-year, two-arm, randomized, double-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema.
KESTREL (CRTH258B2301) A two-year, three-arm, randomized, double-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema.
NEMO (NRAS melanoma and MEK inhibitor) A randomized phase III, open label, multicenter, two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unrespectable or metastatic NRAS mutation-positive melanoma.
OCRELIZUMAB (WA25046) A phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of Ocrelizumab in adults with primary progressive multiple sclerosis.
OCRELIZUMAB (WA21092, WA21093) A phase III randomized, double-blinded, double dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis
TONE (EudraCt No.: 2013-002515-10) A phase III study for treatment of optic neuritis with erythropoietin: a randomised, double-blind, placebo-controlled trial; TONE (P000053).
TOLERANT STUDY A phase IV randomised, controlled study investigating the efficacy and safety of aflibercept “Treat and Extend” using a strict retreatment regimen compared to a relaxed retreatment regimen in patients with exudative age-related macular degeneration (AMD).